SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as discussions swirl around its AI capabilities and potential market competition with NVDA. Community members are highlighting Google's advancements in TPU technology and the possibility of Meta utilizing Google's chips. Bullish sentiment is fueled by perceived undervaluation relative to growth prospects and comparisons to other tech giants.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as chatter swirls around its AI chip ambitions and potential partnerships with companies like Meta, possibly challenging NVDA's dominance. The community is closely watching the stock's momentum, debating whether it's overbought and discussing potential price targets amid the AI race. Some investors believe GOOG is undervalued relative to its growth potential, while others are wary of a possible pullback.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending as the stock experiences significant price movement, fueled by a surprise third-quarter profit and raised full-year guidance which is driving short covering. The community is discussing the potential for a short squeeze and whether the company's turnaround strategy is gaining traction. Investors are weighing positive earnings results against concerns about revenue and long-term growth.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic Inc. ($SYM) is trending due to positive investor sentiment following strong revenue growth and a substantial order backlog, fueled by the increasing demand for warehouse automation. Community discussions revolve around the company's growth potential and strategic partnerships with major retailers such as Walmart, while some analysts point to a lofty valuation as a cause for caution. Bullish investors view the stock as a long-term play in warehouse automation, while bears are pointing to a possible retest of lower prices.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc is trending as chatter revolves around potential news catalysts and a possible short squeeze. Community members are closely watching for updates on the Star 26 Capital acquisition, while also speculating on the impact of upcoming AI and defense technology showcases. Increased trading volume and a low float contribute to the heightened interest in NUKK.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch ($ANF) is trending following an earnings report, with community members weighing in on the results and future outlook. Discussion centers around whether the stock is overbought, oversold, or represents a strong buying opportunity, highlighting the debate around its valuation and potential for a short squeeze.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to community discussion around a CMS decision's potential impact on the company's future, despite recent strong earnings and revenue growth. The community is weighing the confusion surrounding the decision's long-term implications against the company's growth and strategic investments, with some expressing concern about potential dilution and executive selling, while others remain optimistic about the company's pipeline and future profitability. Several messages also point to possible market manipulation in the stock.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

IMSR is trending as investors discuss its potential within the nuclear energy sector, particularly in comparison to peers like OKLO and SMR. Community members are weighing the impact of potential catalysts such as timelines for the Texas A&M Rellis pilot and SDA approval from the NRC. Some express concerns about dilution and recent price declines.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as community members discuss its potential as a high-throughput, compliance-focused blockchain aimed at bridging traditional finance with crypto, highlighting comparisons to established projects like Solana and XRP. The community is particularly focused on KTA's capacity for millions of transactions per second and integration of KYC/AML features, positioning it as infrastructure ready for institutional adoption. Eric Schmidt's backing is frequently mentioned as a validation of this vision.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad ($MON) is trending as the community discusses its potential as a high-speed, low-fee, and EVM-compatible layer one solution, drawing comparisons to Solana and Ethereum; some users are excited about its early hype and recent listing on Coinbase. Community members are actively speculating on price targets and debating whether to increase their positions, while closely watching transaction speeds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead...

Neo Ivy Capital Management Purchases New Shares in Arrowhead Pharmaceuticals, Inc. $ARWR

Neo Ivy Capital Management acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the second quarter, according to the company in its most recent disclosure with the...

Equities Analysts Set Expectations for ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 3% - Here's What Happened

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 3% - Here's What Happened...

Traders Purchase High Volume of Arrowhead Pharmaceuticals Call Options (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Traders acquired 7,629 call options on the company. This...

Noteworthy Thursday Option Activity: ARWR, RBLX, COF

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Arrowhead Pharmaceuticals Inc (Symbol: ARWR), where a total volume of 8,414...

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 5.4% in the second quarter, according to its most recent Form 13F filing with the...

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an...

Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board increased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 112.7% in the second quarter, according to its most recent 13F filing with...

Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) will be releasing its Q4 2025 earnings after the market closes on Tuesday, November 25. (View Earnings Report at...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.11	--	--	N/A
Q3 '25	-$0.95	-$1.26	-32.32%	MISSED
Q2 '25	-$0.44	$2.75	722.20%	BEAT
Q1 '25	-$0.41	-$1.39	-243.03%	MISSED
Q4 '24	-$0.97	-$1.36	-40.14%	MISSED

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ARWR News

ARWRArrowhead Pharmaceuticals Inc.